Pugh Christopher William, Ratcliffe Peter John
Oxygen-sensing Group, Henry Wellcome Building for Genomic Medicine, University of Oxford, Roosevelt Drive, Headington, Oxford OX3 7BN, UK.
Semin Cancer Biol. 2003 Feb;13(1):83-9. doi: 10.1016/s1044-579x(02)00103-7.
Recently, work on the mechanism of action of the von Hippel-Lindau tumour suppressor protein (pVHL) and studies on hypoxic gene regulation have converged, providing insights into both cellular oxygen sensing and cancer pathogenesis. pVHL is the recognition component of the E3-ubiquitin ligase complex involved in the degradation of hypoxia-inducible factor-1 (HIF) alpha-subunits, a process regulated by oxygen availability and blocked by disease causing pVHL mutations. In normoxic cells, pVHL targeting of HIF-alpha subunits follows hydroxylation of critical HIF prolyl residues by a group of oxygen, 2-oxoglutarate- and iron-dependent enzymes. In this review, we outline current understanding of HIF/pVHL/prolyl hydroxylase pathway and consider the implications for VHL-associated cancer.
最近,关于冯·希佩尔-林道肿瘤抑制蛋白(pVHL)的作用机制研究与缺氧基因调控研究取得了一致进展,为细胞氧感知和癌症发病机制提供了深入见解。pVHL是E3泛素连接酶复合物的识别成分,参与缺氧诱导因子-1(HIF)α亚基的降解,这一过程受氧可用性调节,并因导致pVHL突变的疾病而受阻。在常氧细胞中,pVHL对HIF-α亚基的靶向作用发生在一组氧、2-氧代戊二酸和铁依赖性酶对关键HIF脯氨酰残基进行羟基化之后。在本综述中,我们概述了目前对HIF/pVHL/脯氨酰羟化酶途径的理解,并探讨了其对VHL相关癌症的影响。